PMID- 29025760
OWN - NLM
STAT- MEDLINE
DCOM- 20180601
LR  - 20181113
IS  - 1942-3268 (Electronic)
IS  - 1942-325X (Print)
IS  - 1942-3268 (Linking)
VI  - 10
IP  - 5
DP  - 2017 Oct
TI  - Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic 
      Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease.
PG  - e001625
LID - e001625 [pii]
LID - 10.1161/CIRCGENETICS.116.001625 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is the treatment of choice in 
      Kawasaki disease (KD). IVIG is used to prevent cardiovascular complications 
      related to KD. However, a proportion of KD patients have persistent fever after 
      IVIG treatment and are defined as IVIG resistant. METHODS AND RESULTS: To develop 
      a risk scoring system based on genetic markers to predict IVIG responsiveness in 
      KD patients, a total of 150 KD patients (126 IVIG responders and 24 IVIG 
      nonresponders) were recruited for this study. A genome-wide association analysis 
      was performed to compare the 2 groups and identified risk alleles for IVIG 
      resistance. A weighted genetic risk score was calculated by the natural log of 
      the odds ratio multiplied by the number of risk alleles. Eleven single-nucleotide 
      polymorphisms were identified by genome-wide association study. The KD patients 
      were categorized into 3 groups based on their calculated weighted genetic risk 
      score. Results indicated a significant association between weighted genetic risk 
      score (groups 3 and 4 versus group 1) and the response to IVIG (Fisher's exact P 
      value 4.518x10(-)(03) and 8.224x10(-)(10), respectively). CONCLUSIONS: This is 
      the first weighted genetic risk score study based on a genome-wide association 
      study in KD. The predictive model integrated the additive effects of all 11 
      single-nucleotide polymorphisms to provide a prediction of the responsiveness to 
      IVIG.
CI  - (c) 2017 The Authors.
FAU - Kuo, Ho-Chang
AU  - Kuo HC
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Wong, Henry Sung-Ching
AU  - Wong HS
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Chang, Wei-Pin
AU  - Chang WP
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Chen, Ben-Kuen
AU  - Chen BK
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Wu, Mei-Shin
AU  - Wu MS
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Yang, Kuender D
AU  - Yang KD
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Hsieh, Kai-Sheng
AU  - Hsieh KS
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Hsu, Yu-Wen
AU  - Hsu YW
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Liu, Shih-Feng
AU  - Liu SF
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Liu, Xiao
AU  - Liu X
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.).
FAU - Chang, Wei-Chiao
AU  - Chang WC
AD  - From the Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, 
      School of Pharmacy (H.-C.K., W.-C.C.), Department of Clinical Pharmacy, School of 
      Pharmacy (H.S.-C.W., M.-S.W., W.-C.C.), School of Health Care Administration, 
      College of Management (W.-P.C.), and PhD Program in Biotechnology Research and 
      Development, College of Pharmacy (W.-C.C.), Taipei Medical University, Taiwan; 
      Department of Pediatrics and Kawasaki Disease Center (H.-C.K., K.-S.H.), Division 
      of Pulmonary and Critical Care Medicine, Department of Internal Medicine 
      (S.-F.L.), and Department of Respiratory Therapy (S.-F.L.), Kaohsiung Chang Gung 
      Memorial Hospital, Taiwan; Department of Pharmacology, College of Medicine, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, 
      National Cheng Kung University, Tainan, Taiwan (B.-K.C.); Department of 
      Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan (K.D.Y.); Institute of 
      Clinical Medicine, National Yang Ming University, Taipei, Taiwan (K.D.Y.); The 
      PhD Program for Translational Medicine, College of Medical Science and 
      Technology, Taipei Medical University and Academia Sinica, Taiwan (Y.-W.H.); 
      Section of Hematology/Oncology, Department of Medicine, The University of 
      Chicago, IL (X.L.); Department of Pharmacy, Taipei Medical University-Wanfang 
      Hospital, Taiwan (W.-C.C.); and Center for Biomarkers and Biotech Drugs, 
      Kaohsiung Medical University, Taiwan (W.-C.C.). wcc@tmu.edu.tw.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Circ Cardiovasc Genet
JT  - Circulation. Cardiovascular genetics
JID - 101489144
RN  - 0 (3' Untranslated Regions)
RN  - 0 (ADTRP protein, human)
RN  - 0 (DNA, Intergenic)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (KLF6 protein, human)
RN  - 0 (Kruppel-Like Factor 6)
RN  - 0 (MIRN548 microRNA, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (Repressor Proteins)
RN  - 0 (ZEB1 protein, human)
RN  - 0 (ZNF438 protein, human)
RN  - 0 (ZPLD1 protein, human)
RN  - 0 (Zinc Finger E-box-Binding Homeobox 1)
SB  - IM
CIN - Circ Cardiovasc Genet. 2017 Oct;10(5):. PMID: 29025763
EIN - Circ Cardiovasc Genet. 2017 Dec;10(6):e000040. PMID: 30576607
MH  - 3' Untranslated Regions
MH  - Alleles
MH  - Area Under Curve
MH  - Child, Preschool
MH  - Chromosomes, Human, Pair 6
MH  - DNA, Intergenic/genetics
MH  - Female
MH  - Genetic Loci
MH  - *Genome-Wide Association Study
MH  - Genotype
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Infant
MH  - Kruppel-Like Factor 6/genetics
MH  - Male
MH  - Membrane Proteins/genetics
MH  - MicroRNAs/genetics
MH  - Mucocutaneous Lymph Node Syndrome/drug therapy/*genetics/pathology
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide
MH  - Principal Component Analysis
MH  - ROC Curve
MH  - Repressor Proteins/genetics
MH  - Risk Factors
MH  - Treatment Failure
MH  - Zinc Finger E-box-Binding Homeobox 1/genetics
PMC - PMC5647111
OTO - NOTNLM
OT  - alleles
OT  - genetics
OT  - genome-wide association study
OT  - odds ratio
OT  - pharmacogenetics
EDAT- 2017/10/14 06:00
MHDA- 2018/06/02 06:00
PMCR- 2017/10/18
CRDT- 2017/10/14 06:00
PHST- 2016/09/22 00:00 [received]
PHST- 2017/07/27 00:00 [accepted]
PHST- 2017/10/14 06:00 [entrez]
PHST- 2017/10/14 06:00 [pubmed]
PHST- 2018/06/02 06:00 [medline]
PHST- 2017/10/18 00:00 [pmc-release]
AID - CIRCGENETICS.116.001625 [pii]
AID - 10.1161/CIRCGENETICS.116.001625 [doi]
PST - ppublish
SO  - Circ Cardiovasc Genet. 2017 Oct;10(5):e001625. doi: 
      10.1161/CIRCGENETICS.116.001625.